What is SRRK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.14B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SRRK?

P/E (TTM) is n/a and 52-week range is $27.07 to $61.76 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SRRK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SRRK?

The company profile lists revenue (TTM) near $47M, net income (TTM) near $-11.21B, EPS (TTM) near $-3.30 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Scholar Rock Holding Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 119.8M shares outstanding, ISIN US80706P1030 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Scholar Rock Holding Corp

$SRRK

Health Care · Biotechnology

IR Run Scenarios

$42.19

-0.02%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The firm focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Employees

289

Website

scholarrock.com/

IPO

2018-05-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)